Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Clostridium butyricum + Nivolumab & Non-small-cell lung cancer (NSCLC), the retrospective trial XXX - Atezolizumab + Clostridium butyricum CBM588 vs Clostridium butyricum CBM588 + Nivolumab vs Clostridium butyricum CBM588 + Pembrolizumab vs Nivolumab vs Atezolizumab vs Pembrolizumab & Non-small-cell lung cancer (NSCLC) revealed that probiotic Clostridium butyricum CBM588 may have a positive impact on therapeutic efficacy of Immune Checkpoint Inhibitors (ICIs) & Non-small-cell lung carcinoma (NSCLC)
Tomita et al. 2020 Cancer…